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CP is the most common cause of chronic disability in childhood occurring in 2–2.5/1000
births. It is a severe disorder and a significant number of patients present cognitive
delay and difficulty in walking. The use of botulinum toxin (BTX) has become a popular
treatment for CP especially for spastic and dystonic muscles while avoiding deformity
and pain. Moreover, the combination of physiotherapy, casting, orthotics and injection of
BTXmay delay or decrease the need for surgical intervention while reserving single-event,
multi-level surgery for fixed musculotendinous contractures and bony deformities in older
children. This report highlights the utility of BTX in the treatment of cerebral palsy in
children. We include techniques for administration, side effects, and possible resistance
as well as specific use in the upper and lower limbs muscles.
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INTRODUCTION
Cerebral palsy (CP) is a group of permanent, non-progressive disorders of movement and posture
resulting in activity limitations and forced dysmorphisms. CP is not a disease or a single entity but
rather a complex cerebral disorder with final expression in different etiological events (Pavone and
Testa, 2015). The etiologic events act in an early phase of fetal and infant cerebral development.
The disorder not only affects motor activity but is also often associated with other disturbances
involving sensation, perception, communication and behavior. Cognitive delay and epileptic crises
are frequently observed in these patients.
CP is the most common cause of chronic disability in childhood occurring in 2–2.5%0 of births.
The risk of CP is 20–30 times more common in newborns of low birth weight. It is 1.4%0
for newborns 2500 g and 78%0 in newborns below 1000 g. Predisposing factors include maternal
disorders such as gestosis, twin birth, intellective delay, miscarriages, placental anomalies as well as
prematurity, low intra-uterine development, and neonatal encephalopathies (Pavone and Pavone,
2006).
Etiological factors that cause CP are primarily hypoxic ischemic encephalopathy and
environmental conditions, but infections as well as metabolic, malformative, and genetic disorders
are also frequently reported. Such conditions affect the CNS during pregnancy, at birth, or during
the first 2 years of postnatal life and act on the first motor neuron and decrease the excitatory and
regulatory input. The lesions from the cortex through the reticulo-spinal and cortico-spinal tracts
reach the lower motor neuron localized in brain stem and spinal cord (MacLennan, 1999; Moreno-
De Luca et al., 2012). The anomalous input results in impaired motor control and increased
alfa-motoneuron excitability causing spasticity.
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Several CP classifications have been proposed based on the
localization of the cerebral lesions and their clinical expression.
In the past, the spastic form was subdivided into hemiplegic,
diplegic, and tetraplegic; the dyskinetics include choreoathetotic,
dystonic, ballism, ataxic, and finally a mixed form (Cowan et al.,
2003; Morris, 2007). More recently, CP classification has been
based on: (1) the type and severity of motor abnormalities; (2) the
anatomical distribution of the extremities; (3) the characteristics
of the neurologically associated dysfunction; and (4) on the
timing of the presumed causal event (Surveillance of Cerebral
Palsy in Europe, 2002; Christine et al., 2007; Rosenbaum et al.,
2007; Pavone and Testa, 2015).
The “spasticity” sub-type is the most frequent form and is
defined as muscular resistance to stretching or as an excessive
or involuntary muscle activity. Spasticity is characterized by an
initial resistance to passive movement, followed by a sudden
release called the clasp-knife phenomenon. It is associated with
brisk tendon reflexes and an extensor plantar reflex, clonus,
diminished active movements, and disuse atrophy (Haslam,
2007). Spasticity may result in contractures, pain, and bone
lesions with easy fractures. On the other hand, contractures may
worsen or cause spasticity (Ward, 2012).
To measure motor abilities and functional limitations, many
scales and classification systems have been proposed. One of
the most common is the Gross Motor Function Classification
System-Expanded and Revised (GMFCS-ER) proposed by
Palisano (Palisano et al., 1997, 2008; Rethlefsen et al., 2010). This
test distinguishes the functional anomalies according to a scale
with five levels. In level I the patient walks without limitations;
level II walks with limitations; level III walks using a hand-held
mobility device; level IV has limited self-mobility and may use
powered mobility; and level V may be transported in a manual
wheel chair.
Other systems include the Functional Mobility Scale (FMS;
Graham et al., 2004) that is based on interviews with the
parents. This describes the assistance needed for the child to
cover three distances (5, 50, and 500 yards or meters). To assess
manual functionality, the Bimanual FineMotor Function (BFMF;
Beckung and Hagberg, 2002) and Manual Ability Classification
System (MACS; Eliasson et al., 2006) and for Communication
Function (CFCS; Hidecker et al., 2011) have been proposed.
Other systems have been applied to gait (classification of
gait analysis), dystonia [Barry-Albright Dystonia Scale (BAD)],
Dystonia Impairment Scale (DIS; Monbaliu et al., 2012), and
Burke Scale (Burke et al., 1985), as well as for drooling, pain,
speech, and oromotor dysfunction (Pavone and Testa, 2015).
The treatment of CP uses different elements including
communication, social development, emotivity, education, daily
activity, physical aspect, nutrition, and mobility. Physical therapy
goals include stretching, physiotherapy, hydrotherapy, elective
stimulations, and hot/cold treatments.
Pharmacologic therapy includes systemic and focal
treatments. Systemic anti-spasticity drugs include baclofen
and diazepam (used only for short duration). Systemic drugs
can be effective in diffuse spasticity and affect several muscular
groups. However, they are often associated with a number of
intolerable systemic side effects including dizziness, sedation,
confusion, nausea, and vomiting, fatigue, lower seizure threshold,
and central nervous system depression. Focal treatments are
mainly represented by botulinum toxin (BTX). The advantage
of focal BTX is that it directly treats the symptomatic muscles.
When used at recommended doses, it avoids systemic side
effects. This elimination of spastic components is mandatory in
CP treatment because it allows affected individuals to use the
residual component of selective motor control more effectively
and functionally (Rosenbaum et al., 2002; Majnemer and Mazer,
2004).
The use of BTX has become popular for orthopedics as a
treatment for spastic and dystonic muscle. The success of BTX
depends on the adjunctive use of physiotherapy and/or splinting
or casting (Ramachandran and Eastwood, 2006). Moreover,
BTX treatment has demonstrated a beneficial effect on the
reduction of pain associated with focal muscular hyperactivity
(Wissel et al., 2000). In fact, in spasticity, the spasmodic muscle
contraction induces extreme vasculature compression because of
the simultaneous activation of adjacent motor units. Ischemia
eventually gives rise to nociceptive pain (ischemic muscular
pain). As soon as the spasm ends, the blood flow returns to
normal, and the pain quickly recedes. BTX improves muscular
pain and reduces this vicious circle by inducingmuscle relaxation
(Restivo et al., 2003).
THE NEUROMUSCULAR JUNCTION
The neuromuscular junction (NMJ) is a synaptic interface
between a branch of the motor neuron and muscle fibers.
It is composed of three elements: pre-synaptic (motor nerve
terminal), intrasynaptic (synaptic basal lamina), and post-
synaptic (muscle fiber and muscle membrane; Cowan et al.,
2003).
BOTULINUM TOXIN. MECHANISM OF
ACTION
Clostridium botulinum produces non-toxic proteins and a
complex mixture of proteins containing botulinum neurotoxin
(Surveillance of Cerebral Palsy in Europe, 2002).There are seven
serotypes of neurotoxin: Botulinum toxin A (BTX-A), Botulinum
toxin B (BTX-B), Botulinum toxin C (BTX-C), Botulinum toxin
D (BTX-D), Botulinum toxin E (BTX-E), Botulinum toxin F
(BTX-F), and Botulinum toxin G (BTX-G). All of these proteins
can inhibit release of acetylcholine from nerve terminals, but
there are some differences about their potency, duration of effect
and intracellular protein targets (Jankovic and Schwartz, 1995;
Aoki and Guyer, 2001).
This mechanism is unique to the mechanism of action of
tetanus toxin. For this reason, BTX has been used in focally
contrasting the muscular hyperactivity associated with tetanus
infection as well as in the treatment of muscular hyperactivity
not-associated with spasticity (Restivo et al., 2002; Restivo and
Marchese-Ragona, 2006; Verderio et al., 2006). BTX-A reduces
muscular activity in a dose-dependent manner. The other BTX
serotypes cleave different proteins of the complex (Arnon et al.,
2001; Koman et al., 2004).
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In about 4 weeks, turnover of the SNARE protein complex
allows exocytosis of acetylcholine to resume. Nerve conduction
is re-established by new axonal sprouting and elongation of
the endplate and by retraction of the new axonal sprouts (de
Paiva et al., 1999). Clinically, muscle relaxation lasts for 12–16
weeks.
TECHNIQUES FOR ADMINISTRATION
The principal commercial preparations of botulinum toxin
are: Botox [OnabotulinumtoxinA, 100 International Units
(IU) per vial; Allergan Inc, Irvine, California]; Dysport
(AbobotulinumtoxinA, 500 IU per vial; IpsenLdt, Slough, United
Kingdom) and Xeomin, a more recently introduced neurotoxin
free of complexing proteins (IncobotulinumtoxinA, 100 IU per
vial; MerzPharma, Germany). Several studies have addressed
the topics of equivalency ratio among the different BTX-A
preparations. Comparative human experimental studies support
dose conversion ratios between Dysport and Botox (ratio D/B)
less than 3:1 (Wohlfarth et al., 2009). The conversion ratio
between Botox and Xeomin is reported to be 1:1 (Poulain et al.,
2013).
To maximize the clinical effectiveness of BTX-A, the toxin
must be injected inside the fascia compartment of the muscle in a
dose suitable of neutralizing the neuromuscular junction activity
and in an adequate volume such that diffusion to the junctions at
the end-plate area occurs while unwanted spread is minimized.
The most effective dosage for the affected muscle is not clear, but
it changes with density of neuromuscular junctions in any given
muscle (Alhusaini et al., 2011). The indicative recommended
doses are 12 units/kg for Botox (Francisco, 2004) and 30 units/Kg
for Dysport (Graham et al., 2000).
Age since 2 years is the best for treatment of lower extremities
for regional or focal impairment and 2 years too for the
upper extremities. There are several muscles involved. The
neuromuscular junctions have age-dependent differences. They
are smaller and higher density in young patients than in adults
(Ma et al., 2002). The dosage must be correlated with weight,
size/volume, level of hypertonia, number of muscles to be
injected, and the underlying weakness. The injection of BTX
could be administered under local or general anesthesia or
with conscious sedation. This depends on patient age, muscular
districts, the number of sites to be treated, and underlying
pathology (Koman et al., 2003).
The timing of the injections is controversial. Most clinicians
agree that the earlier the spasticity is reduced, the better the
outcome. Botulinum toxin can be injected as early as 18 months
of age. There is no upper age limit, however. Once the muscle
is shortened with advanced age, the effect of spasticity relief will
not be as apparent because of contracture (Koman et al., 2003).
The dose advice is for a total maximum dose of 15 IU/kg or
a maximum of 400 IU per injection site. This is a maximum
of 50 IU and a maximum volume per site of 0.5ml. Longer
muscles may require two or more injections. To better focalize
the target muscles, BTX injection is usually performed under
electromyographic (EMG) or ultrasound guidance (Chin et al.,
2005).
BOTULINUM TOXIN: SIDE-EFFECTS
Side-effects are rare when the dosing and technique protocols are
correctly followed (Koman et al., 2003). Adverse events can be
located into the site of injection or can be distant from the site
of injection. Pain at the site of the injection is unlikely a clinical
problem and is usually moderate. The most common side-effect
is weakness in adjacentmuscles caused by diffusion of BTX across
the muscle boundaries (Graham et al., 2000). The BTX diffusion
is strictly dependent on the dilutions that are being used. The
larger the dilution, the higher the risk of diffusion into adjacent
muscles. However, a higher dilution can also represent a strategic
choice of physician. This is especially true for bigger muscles in
which a larger diffusion of BTX may induce a more remarkable
improvement in spasticity. Side-effects distant from the site of
injection are unusual and consist of generalized weakness, flu-like
syndrome, urinary incontinence, constipation and dysphagia.
The most serious side-effect is aspiration pneumonia. This is
critical in CP patients with general involvement and pre-existing
pseudobulbar palsy because in these patients, small amounts of
BTX can worse pharyngeal function (Koman et al., 2003).
Localization of muscles to be injected is based on palpation.
When using BTX, it is important to distinguish large from small
muscles. In fact, large muscles, typically in lower limbs, could be
manually individuated with an accuracy rate of 46–78% (Jankovic
and Schwartz, 1995). This is different from small muscles. Other
methods used to localize the target muscles include ultrasound,
electromyography, and electrical stimulation.
RESISTANCE
A small percent of children may not respond to initial injection
of botulinum toxin. It is important to consider contraindications
before classifying the patient as a “non-responder.” A non-
responder is a child who shows a relative or complete loss of effect
after a second injection. Factors contributing to an inadequate
clinical response include inadequate dosage, inappropriate goals,
or excessive weakness in the affected muscles. Neutralizing
antibodies have also been reported to cause an inadequate
response (Chin et al., 2005).
Resistance to botulinum toxin therapy is characterized by
absence of any beneficial effect and by lack of muscle response
following injection. Antitoxin antibodies are presumed to be
responsible for most cases of resistance. Using the smallest
possible effective dose can prevent development of an antitoxin
antibody. Providers can also extend the time interval between
treatments to at least 3 months. The use of Botulinum toxin B
or F may be beneficial to patients who have developed antibody
resistance (Love et al., 2001).
INDICATIONS FOR USE IN CEREBRAL
PALSY
As the child develops, the spastic muscles frequently fail to grow
as rapidly as neighboring structures. This causes contractures,
deformity and consequent impairment of function. Themuscular
hypertonia may be the primary cause of shortening because even
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normal muscles will become shortened if the tone is persistently
increased (Huet De La Tour et al., 1979). A similar failure of
growth occurs in animals with increased muscle tone such as the
hereditary spastic mouse (Ziv et al., 1984). In contrast, passive
stretching of relaxed muscles may restore normal longitudinal
growth (Holly et al., 1980). Based on this premise, it has been
postulated that this effect could be harnessed to relax overactive
spastic leg muscles by BTXA injections. This hypothesis has been
tested in animal models. BTX A restored the muscle length to
normal and significantly shortened the Achilles tendon length in
the hereditary spastic mice. It did not induce changes in normal
mice (Cosgrove and Graham, 1994).
Injections of BTX determine weakening in spastic muscles
encourages muscle strength and hence muscle growth while
allowing the weak antagonists to be strengthened. This
mechanism avoids the development of bony deformities
secondary to abnormal muscle pull and contracted tendons
and joints. Moreover, a combination of physiotherapy, casting,
orthotics and injection of BTXmay delay or decrease the need for
surgical intervention reserving single-event multi-level surgery
for fixed musculotendinous contractures and bony deformities,
which are common in older children. The success of botulinum
toxin administration depends on many factors. Patient selection
is critical. Children with spasticity who do not have fixed
contractures benefit a great deal from treatment, but patients
with dyskinesia have a variable response. Patients with athetoid
signs do not benefit at all (Gough et al., 2005; Lannin et al.,
2006).
Treatment goals are to attain the next motor milestone, to
allow patient verticalization and to achieve the best possible
locomotion. If the child can walk, the intention is to maintain,
improve, and optimize mobility. In the case of stagnation on a
lower motor level, the aim is to maintain, improve, and optimize
motor function at this level (Koman et al., 2003).
Upper Limb Muscles
In selecting target muscles for BTX injection, it is useful to
evaluate functional deficits and postural deformity and to analyze
the relationships between muscular hypertonia and individual
abilities and disabilities (Lannin et al., 2006). The most common
muscles injected are the biceps brachii for elbow flexor spasticity,
pronator teres for pronated forearm, flexor carpi radialis and
flexor carpi ulnaris for wrist flexion spasticity, and adductor
pollicis for the thumb. The triceps brachii, pectoralis muscles,
teresmajor, and deltoid have been injected for shoulder deformity
(Preiss et al., 2003). There are several injection techniques for
upper limb muscles. To identify the largest muscles, anatomic
knowledge and palpation are sufficient. One should find the
largest bulk of themuscle and inject the toxinmid-belly. The BTX
dose guidelines for upper limb muscle spasticity are reported in
Table 1.
Lower Limbs Muscles
Several studies have shown the short-term efficacy of BTX-
A in the management of spasticity in lower limbs muscles
with improvements in deformity and gait. Injection into the
gastrosoleus is typical for treatment of spastic hemiplegic or
diplegic children including dynamic gait and complex gait
TABLE 1 | General guidelines for use of BOTOX for upper extremity
spasticity (Preiss et al., 2003).
Muscles injected Dose range (IU/Kg of bw) Number of sites
Biceps 2 2–3
Pronator teres 1 1
Flexor carpi radialis 2 1
Flexor carpi ulnaris 2 1
Flexor digitorumsuperficialis 2 1–2
Flexor digitorumprofundus 2 1–2
Flexor pollicislongus 0, 5–1 1
Adductor pollicis 0, 5–1 1
TABLE 2 | General guidelines for use of BOTOX for lower extremity
spasticity (Preiss et al., 2003).
Muscles injected Dose range (IU/Kg of bw) Number of sites
Iliopsoas 2 2
Quadriceps 3–6 4
Medial hamstrings 3–6 3–4
Lateral hamstrings 2–3 2
Adductors 3–6 2
Gastrocnemius 3–6 1–2
Soleus 2–3 1
Tibialis posterior 1–3 1
patterns relate to the equines. It this last case, the equinovarus
deformity could be corrected with injection on the area of tibialis
posterior or tibialis anterior. Injection in the hamstring is used
to treat dynamic flexed genu caused by over-activity of these
muscles. The good response to injection is due to hamstring
lengthening or adductor tenotomy. Injection of the hip flexors
is more technically demanding and may require ultrasound
guidance for accuracy (Graham et al., 2000; Preiss et al., 2003;
Moelenaers et al., 2013).
Muscles to be injected within the adductor or hamstring group
and the appropriate techniques are under debate. In particular,
children with wide involvement may have improvements in
position. Patients with progressive subluxation of the hip may
have improved pain and stiffness after injection of the involved
adductors and iliopsoas, especially when combined with bracing
of the hip in abduction. A reduction or stabilization of the hip
migration percentage may occur—especially in children under
the age of 2 years whose initial subluxation shows a migration
percentage >30%. The BTX dose guidelines for lower limb
muscle spasticity are reported in Table 2.
POST-INJECTION TREATMENT
The antispastic effect appears within 24 h to 3 days after injection
and becomes maximum at 10 days to a month. It lasts for 3–
6 months. Some patients are golden responders in whom the
antispastic effect lasts for over a year. Proper exercises, splinting
and casting may increase the number of golden responders.
Casting for 2–3 weeks after injections may improve the results,
(Pidcock et al., 2005), although it use as a method of applying
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stretch at the time of the injection is inappropriate since the
reduction in stretch reflex and spasticity has not yet had the time
to completely manifest.
CONCLUSION
Botulinum toxin is a powerful neurotoxin that has an established
place in the treatment of spasticity in CP. It can be used as early as
2 years of age and can be combined with other treatment options
as the child grows older when untreated spasticity begins to cause
contractures and deformities. The most common indications
are young diplegic and hemiplegic children. The complex gait
patterns often require treatment at multiple levels in a manner
similar to the development of single-event multilevel surgery
(Heinen et al., 2010).
Factors limiting its use are the high cost that implies a
restriction on the frequency of treatment and the use of a
maximum dose per each session. Moreover, before selecting the
target muscles, it is important that a detailed clinical analysis be
performed including differentiation of dynamic and structural
components of deformity as well as definition of a treatment goal
for the specific patient.
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